Drugs Made In America Acquisition Corp. SEC filings DMAAU

Drugs Made In America Acquisition Corp. has 80 filings in SEC EDGAR's recent list, going back to Aug 1, 2024. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 21, 2026 (material agreement, other events). The company's fiscal year ends on December 31.

Drugs Made In America Acquisition Corp. SEC filings
Form Description Filed Period
425 Current report Oct 21, 2026 —
425 Current report Sep 14, 2026 —
425 Current report Jul 20, 2026 —
425 Current report May 5, 2026 —
DEFR14A Revised definitive proxy statement Apr 16, 2026 —
NT 10-K Notification of late filing Apr 1, 2026 Dec 31, 2025
NT 10-Q Notification of late filing Nov 17, 2025 Sep 30, 2025
NT 10-Q Notification of late filing May 15, 2025 Mar 31, 2025
EFFECT Filing Jan 27, 2025 —
CORRESP Letter to the SEC Jan 23, 2025 —
CORRESP Letter to the SEC Jan 23, 2025 —
CERT Filing Jan 8, 2025 —
EFFECT Filing Jan 7, 2025 —
8-A12B For registration of certain classes Jan 7, 2025 —
CORRESP Letter to the SEC Jan 3, 2025 —
CORRESP Letter to the SEC Jan 3, 2025 —
CORRESP Letter to the SEC Sep 6, 2024 —
UPLOAD Letter from the SEC Aug 27, 2024 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Blank Checks (SIC 6770)
Listed as
DMAA (Nasdaq), DMAAR (Nasdaq), DMAAU (Nasdaq)
Fiscal year ends
December 31
Headquarters
New York, NY
SEC filer status
, Emerging growth company
SEC CIK
2028614

Other Blank Checks companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.